Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock
Cramer favors Howmet, remains cautious on AeroVironment, Rocket, AtaiBeckley and MP Materials, citing competition and limited upside.
Stocks · News reference
Why Is GH Research Stock Trading Higher on Thursday?
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
8-K filing — AtaiBeckley Inc. (ATAI)
Filed: 2026-08-31 AccNo: 0001140361-26-035091 Size: 167 KB Item 8.01: Other Events
President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.